Family history of breast cancer and its association with disease severity and mortality


A family history (FH) of breast cancer (BC) is known to increase an individual's risk of disease onset. However, its role in disease severity and mortality is less clear. We aimed to ascertain associations between FH of BC, severity and BC-specific mortality in a hospital-based cohort of 5354 women with prospective information on FH. We included women diagnosed at Guy's and St Thomas’ NHS Foundation Trust between 1975 and 2012 (n = 5354). BC severity was defined and categorized as good, moderate, and poor prognosis. Data on BC-specific mortality was obtained from the National Cancer Registry and medical records. Associations between FH and disease severity or BC-specific mortality were evaluated using proportional odds models and Cox proportional hazard regression models, respectively. Available data allowed adjustment for potential confounders (e.g., treatment, socioeconomic status, and ethnicity). FH of any degree was not associated with disease severity at time of diagnosis (adjusted proportional OR: 1.00 [95% CI: 0.85 to 1.17]), which remained true also after stratification by period of diagnosis. FH of BC was not associated with BC-mortality HR: 0.99 (95% CI: 0.93 to 1.05). We did not find evidence to support an association between FH of BC and severity and BC-specific mortality. Our results indicate that clinical management should not differ between women with and without FH, when the underlying mutation is unknown.

Keywords:
breast cancer, Family history, mortality, severity


Autoři: Jennifer C. Melvin 1;  Wahyu Wulaningsih 1;  Zac Hana 1;  Arnie D. Purushotham 2,3;  Sarah E. Pinder 2,3;  Ian Fentiman 4;  Cheryl Gillett 2;  Anca Mera 1;  Lars Holmberg 1,5,6;  Mieke Van Hemelrijck 1,*
Působiště autorů: Faculty of Life Sciences and Medicine, Division of Cancer Studies, Cancer Epidemiology Group, King's College London, London, United Kingdom 1;  Faculty of Life Sciences and Medicine, Division of Cancer Studies, Section of Research Oncology, King's College London, London, United Kingdom 2;  Guy's and St. Thomas’ NHS Foundation Trust, London, United Kingdom 3;  Regional Cancer Centre, Uppsala/Orebro, Uppsala, Sweden 4;  Research Oncology, Guy's Hospital, London, United Kingdom 5;  Department of Surgical Sciences, Uppsala University, Uppsala, Sweden 6
Vyšlo v časopise: Cancer Medicine 2016; 5(5)
Kategorie: Original Research
prolekare.web.journal.doi_sk: 10.1002/cam4.648

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Souhrn

A family history (FH) of breast cancer (BC) is known to increase an individual's risk of disease onset. However, its role in disease severity and mortality is less clear. We aimed to ascertain associations between FH of BC, severity and BC-specific mortality in a hospital-based cohort of 5354 women with prospective information on FH. We included women diagnosed at Guy's and St Thomas’ NHS Foundation Trust between 1975 and 2012 (n = 5354). BC severity was defined and categorized as good, moderate, and poor prognosis. Data on BC-specific mortality was obtained from the National Cancer Registry and medical records. Associations between FH and disease severity or BC-specific mortality were evaluated using proportional odds models and Cox proportional hazard regression models, respectively. Available data allowed adjustment for potential confounders (e.g., treatment, socioeconomic status, and ethnicity). FH of any degree was not associated with disease severity at time of diagnosis (adjusted proportional OR: 1.00 [95% CI: 0.85 to 1.17]), which remained true also after stratification by period of diagnosis. FH of BC was not associated with BC-mortality HR: 0.99 (95% CI: 0.93 to 1.05). We did not find evidence to support an association between FH of BC and severity and BC-specific mortality. Our results indicate that clinical management should not differ between women with and without FH, when the underlying mutation is unknown.

Keywords:
breast cancer, Family history, mortality, severity


Zdroje

1 Slattery, M. L., and R. A. Kerber. 1993. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. Jama. 270:1563–8.

2 Pharoah, P. D., N. E. Day, S. Duffy, D. F. Easton, and B. A. Ponder. 1997. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int. J. Cancer 71:800–9.

3 Ramsey, S. D., P. Yoon, R. Moonesinghe, and M. J. Khoury. 2006. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet. Med. 8:571–5.

4 Molino, A., M. Giovannini, R. Pedersini, M. Frisinghelli, R. Micciolo, M. Mandara, et al. 2004. Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br. J. Cancer 91:96–8.

5 Thalib, L., S. Wedren, F. Granath, H. O. Adami, B. Rydh, C. Magnusson, et al. 2004. Breast cancer prognosis in relation to family history of breast and ovarian cancer. Br. J. Cancer 90:1378–81.

6 Collaborative Group on Hormonal Factors in Breast. 2001. C. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–99.

7 Anderson, D. E., and M. D. Badzioch. 1986. Survival in familial breast cancer patients. Cancer 58:360–5.

8 Chang, E. T., R. L. Milne, K. A. Phillips, J. C. Figueiredo, M. Sangaramoorthy, T. H. Keegan, et al. 2009. Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. Breast Cancer Res. Treat. 117:167–76.

9 Israeli, D., P. I. Tartter, S. T. Brower, B. Mizrachy, and J. Bratton. 1994. The significance of family history for patients with carcinoma of the breast. J. Am. Coll. Surg. 179:29–32.

10 Ruder, A. M., P. F. Moodie, N. A. Nelson, and N. W. Choi. 1988. Does family history of breast cancer improve survival among patients with breast cancer? Am. J. Obstet. Gynecol. 158:963–8.

11 Russo, A., A. Herd-Smith, D. Gestri, S. Bianchi, V. Vezzosi, M. Rosselli Del Turco, et al. 2002. Does family history influence survival in breast cancer cases? Int. J. Cancer 99:427–30.

12 Schouten, L. J., P. S. Hupperets, J. J. Jager, L. Volovics, J. A. Wils, A. L. Verbeek, et al. 1997. Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res. Treat. 43:217–23.

13 Albano, W. A., J. A. Recabaren, H. T. Lynch, A. S. Campbell, J. A. Mailliard, C. H. Organ, et al. 1982. Natural history of hereditary cancer of the breast and colon. Cancer 50:360–3.

14 Fukutomi, T., Y. Kobayashi, T. Nanasawa, H. Yamamoto, and H. Tsuda. 1993. A clinicopathological analysis of breast cancer in patients with a family history. Surg. Today 23:849–54.

15 Langlands, A. O., G. R. Kerr, and S. M. Bloomer. 1976. Familial breast cancer. Clin. Oncol. (R. Coll. Radiol.) 2:41–5.

16 Lynch, H. T., W. A. Albano, J. A. Recabaren, P. R. Fain, and P. M. Lynch.1981. Survival in hereditary breast and colon cancer. JAMA: J. American Med. Assoc.. 246:1197.

17 Malone, K. E., J. R. Daling, D. R. Doody, C. O'Brien, A. Resler, E. A. Ostrander, et al. 2011. Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol. Biomarkers Prev. 20:2560–71.

18 Malone, K. E., J. R. Daling, N. S. Weiss, B. McKnight, E. White, and L. F. Voigt. 1996. Family history and survival of young women with invasive breast carcinoma. Cancer 1:1417–25.

19 Mohammed, S. N., P. Smith, S. V. Hodgson, I. S. Fentiman, D. W. Miles, D. M. Barnes, et al. 1998. Family history and survival in premenopausal breast cancer. Br. J. Cancer 77:2252–6.

20 Wobbes, T., M. P. van de Wiel, R. F. van der Sluis, and A. G. Theeuwes. 1987. The effect of familiality on clinical presentation and survival in mammary carcinoma. Eur. J. Surg. Oncol. 13:119–21.

21 Goldhirsch, A., J. H. Glick, R. D. Gelber, A. S Coates, and H. J. Senn. 2001. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J. Clin. Oncol. 19:3817–27.

22 van Schoor, G., S. M. Moss, J. D. Otten, R. Donders, E. Paap, G. J. den Heeten, et al. 2011. Increasingly strong reduction in breast cancer mortality due to screening. Br. J. Cancer 104:910–4.

23 Loman, N., O. Johannsson, U. Kristoffersson, H. Olsson, and A. Borg. 2001. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J. Natl Cancer Inst. 93:1215–23.

24 Malone, K. E., J. R. Daling, C. Neal, N. M. Suter, C. O'Brien, K. Cushing-Haugen, et al. 2000. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393–402.

25 Pathology of familial breast cancer : differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases.. 1997. Breast Cancer Linkage Consortium. Lancet 349:1505–10.

26 Adem, C., C. Reynolds, C. L. Soderberg, J. M. Slezak, S. K. McDonnell, T. J. Sebo, et al. 2003. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1–11.

27 Chappuis, P. O., V. Nethercot, and W. D. Foulkes. 2000. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin. Surg. Oncol. 18:287–95.

28 Honrado, E., J. Benitez, and J. Palacios. 2006. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit. Rev. Oncol. Hematol. 59:27–39.

29 Lakhani, S. R., J. Jacquemier, J. P. Sloane, B. A. Gusterson, T. J. Anderson, M. J. van de Vijver, et al. 1998. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 90:1138–45.

30 Palacios, J., E. Honrado, A. Osorio, A. Cazorla, D. Sarrio, A. Barroso, et al. 2003. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 9(10 Pt 1):3606–14.

31 Porter, D. E., B. B. Cohen, M. R. Wallace, E. Smyth, U. Chetty, J. M. Dixon, et al. 1994. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br. J. Surg. 81:1512–5.

32 Rubin, S. C., I. Benjamin, K. Behbakht, H. Takahashi, M. A. Morgan, V. A. LiVolsi, et al. 1996. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 7:1413–6.

33 Foulkes, W. D., N. Wong, J. S. Brunet, L. R. Begin, J. C. Zhang, J. J. Martinez, et al. 1997. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin. Cancer Res. 3(12 Pt 1):2465–9.

34 Slattery, M. L., T. D. Berry, and R. A. Kerber. 1993. Is survival among women diagnosed with breast cancer influenced by family history of breast cancer? Epidemiology 4:543–8.

35 Jobsen, J. J., J. van der Palen, M. Brinkhuis, F. Ong, and H. Struikmans. 2015. Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer. Acta Oncol. 23:1–6.

36 Breast Cancer Care. 2010. http://www.nhs.uk/ipgmedia/national/Breast%20Cancer%20Care/Assets/InvasivelobularbreastcancerBCC11pages.pdf Invasive Lobular Breast Cancer: Factsheet. London

37 Margolin, S., H. Johansson, L. E. Rutqvist, A. Lindblom, and T. Fornander. 2006. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam. Cancer 5:309–21.

38 Figueiredo, J. C., M. Ennis, J. A. Knight, J. R. McLaughlin, N. Hood, F. O'Malley, et al. 2007 Sep. Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res. Treat. 105:69–80.

39 Eccles, B. K., E. R. Copson, R. I. Cutress, T. Maishman, D. G. Altman, P. Simmonds, et al. 2015 Jul. Family history and outcome of young patients with breast cancer in the UK (POSH study). Br. J. Surg. 102:924–35.

40 Arpino, G., M. Milano, and S. De Placido. 2015. Features of aggressive breast cancer. Breast 24:594–600.

41 Hao, S., Y. Liu, K. D. Yu, S. Chen, W. T. Yang, and Z. M. Shao. 2015. Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women. PLoS ONE 10:e0129741.

42 Park, S., W. Han, J. Kim, M. K. Kim, E. Lee, T. K. Yoo, et al. 2015. Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence. J. Breast Cancer 18:160–6.

Štítky
Onkológia

Článok vyšiel v časopise

Cancer Medicine

Číslo 5

2016 Číslo 5

Najčítanejšie v tomto čísle

Tejto téme sa ďalej venujú…


Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

nový kurz
Autori: MUDr. Petr Výborný, CSc., FEBO

Autori: MUDr. Jiří Horažďovský, Ph.D

Zánětlivá bolest zad a axiální spondylartritida – Diagnostika a referenční strategie
Autori: MUDr. Monika Gregová, Ph.D., MUDr. Kristýna Bubová

Krvácení v důsledku portální hypertenze při jaterní cirhóze – od pohledu záchranné služby až po závěrečný hepato-gastroenterologický pohled
Autori: PhDr. Petr Jaššo, MBA, MUDr. Hynek Fiala, Ph.D., prof. MUDr. Radan Brůha, CSc., MUDr. Tomáš Fejfar, Ph.D., MUDr. David Astapenko, Ph.D., prof. MUDr. Vladimír Černý, Ph.D.

Rozšíření možností lokální terapie atopické dermatitidy v ordinaci praktického lékaře či alergologa
Autori: MUDr. Nina Benáková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa